宫颈鳞状上皮癌化疗前后Bcl-2、eIF-4E和VEGF的变化  

作　　者：吕荣君 滕利 刘佳 

机构地区：吉林省妇幼保健院,吉林长春130061

出　　处：《中国保健》2008年第14期552-554,共3页Chinese Health Care

摘　　要：目的：宫颈癌是最常见的妇科恶性肿瘤，严重威胁患者的生命安全。近年来随着分子生物学技术的发展，以癌基因的激活、抑癌基因的失活以及其相关蛋白表达异常在发病机制方面的研究日益受到重视并取得很大的进展。本实验目的在于探讨宫颈鳞状上皮癌（SCC）化疗效果与组织标本中的Bcl-2、eIF-4E及VEGF的关系。方法：以肿瘤直径大于4cm的宫颈鳞状上皮癌患者48例（Ib期：12例，Ⅱ期：36例）为对象，采用奈得铂、异环磷酰胺、硫酸培洛霉素（SIP疗法）治疗1—2个疗程．磁共振成像判断疗效；采用免疫组化法（sP法）测量组织标本中的Bcl-2、Eif-4及VEGF的阳性率。结果：48例患者治疗1个疗程后，有效28例，无效20例，有效率58．8％，有效病例1疗程结束时肿瘤体积较治疗前明显缩小，Bcl-2及VEGF明显降低。结论：1疗程结束后组织标本中的Bcl-2及VEGF的变化可以预测宫颈鳞状上皮癌术前化疗效果。Objective：Cervical cancer is the most common malignant tumor in Gynecology, its etiology and meehanisms is notclarified. Recently, with the development of the Molecular Biochemicals,the research in oneogcne activation, anti -oncogene inactivation and ectopic expression of its related proteins are reconstructed and make great progress： To evaluate the efficacy of neoadjuvant chemotherapy （NAC）with nedap latin, ifo slam ide and Pep lomyein （SIP） for patients with locally advanced squamaceous cell carcinoma of cervix, and to determine whether Or not Bcl - 2 ,eIF - 4E and VEGF labeling index （LI） obtained from blopsyspocimen swere useful as predictors Of NAC response. Methods：Forty - eight cases （stage Ⅰ b： 12 and Ⅲ： 36） of cervical carcinoma with more than 4 cm in diameter were treated with 1 of SIP therapy followed bv surgery. The response to SIP was measured by magnetic resonance imaging（ M R I）. The relationship of response and Bcl -2 ,eIF -4E and VEGF LI in the biopsyspecimen swere investiged before and after SIP therapy. Conclusion：Seven cases resulte dinpartial response （PR.） and 5 cases did not change （NC） ,the ef- fective rate was 58.8%. In cases with PR, tumor size reduced markedly after the first course of SIP and Bcl -2 ,EIF -4E and VEGF decreased. Conelusion：NAC with nedaplatin, ifo sfam ide and pep lomycin was effective for patients with locally advanced squamaceous cell carcinoma of cervix. Alterations of Bcl- 2 ,and VEGF can be predictors for NAC.

关 键 词：宫颈鳞状上皮癌 化疗 BCL-2 EIF-4E VEGF 

分 类 号：R737.33[医药卫生—肿瘤;医药卫生—临床医学]